Evaluation of the effectiveness and safety of disitamab vedotin for HER2-expressing advanced or recurrent gynecological cancers.

Authors: Lei Yuan, Yiting Bao

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e17512

Source: Full article

---

Abstract

e17512